Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Chronic Hepatitis B

In brief

The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.

Key facts

Study ID
NCT02932150
Run by
Gilead Sciences
People needed
150
Starts
2016-11-01
Expected to finish
2029-10-01
Last updated by the study team
2026-06-18

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.